Erste Asset Management Gmb H Arvinas, Inc. Transaction History

Erste Asset Management Gmb H

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 26, 2024	SELL	$26.15 - $37.26 $523,000 - $745,200	-20,000 Closed	0 $0
Q4 2022 Nov 26, 2024	SELL	$32.47 - $57.24 $649,400 - $1.14 Million	-20,000 Closed	0 $0
Q3 2022 Nov 26, 2024	BUY	$41.87 - $57.99 $837,400 - $1.16 Million	20,000 New	20,000 $896 Million
Q2 2022 Nov 26, 2024	BUY	$36.01 - $74.24 $720,200 - $1.48 Million	20,000 New	20,000 $873 Million
Q1 2022 Nov 22, 2024	SELL	$60.27 - $81.57 $162,729 - $220,238	-2,700 Reduced 11.89%	20,000 $1.28 Billion
Q4 2021 Nov 22, 2024	BUY	$65.85 - $96.21 $1.49 Million - $2.18 Million	22,700 New	22,700 $1.81 Billion
Q2 2021 Nov 22, 2024	BUY	$60.45 - $84.26 $755,625 - $1.05 Million	12,500 Added 122.55%	22,700 $1.73 Billion
Q4 2020 Nov 22, 2024	BUY	$20.19 - $84.93 $205,938 - $866,286	10,200 New	10,200 $822 Million

230

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $969M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.